References

  1. ETHYOL [prescribing information]. Nashville, TN; Cumberland Pharmaceuticals Inc; May 2017.
  2. de Almeida Pdel V, Gregio AM, Machado MA, de Lima AA, Azevedo LR. Saliva composition and functions: a comprehensive review. J Contemp Dent Pract. 2008;9(3):72–80.
  3. Pinna R, Campus G, Cumbo E, Mura I, Milia E. Xerostomia induced by radiotherapy: an overview of the physiopathology, clinical evidence, and management of the oral damage. Ther Clin Risk Manag. 2015;11:171-188.
  4. Tanasiewicz M, Hildebrandt T, Obersztyn I. Xerostomia of various etiologies: a review of the literature. Adv Clin Exp Med. 2016;25(1):199-206.
  5. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist. 2007;12(6):738-747.
  6. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18(19):3339-3345.
  7. Lobo, V., A. Patil, A. Phatak, et al. Free Radicals, Antioxidants and Functional Foods: Impact on Human Health. Pharmacognosy Reviews. 2010;4(8):118–126.
  8. Wasserman TH, Brizel DM, Henke M, et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys. 2005;63(4):985-990.
  9. National Cancer Institute. Eating hints for cancer patients before, during, and after treatment. Available at: https://www.cancer.gov/publications/patient-education/eatinghints.pdf. Accessed June 2017.